Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. (referred to as "Jianda Zhixin") expects a positive increase in net profit for the fiscal year 2025, with projections indicating a net profit of between 242 million to 296 million yuan, representing a year-on-year growth of 6.00% to 29.65% [1] Group 1 - The expected net profit attributable to shareholders is projected to be between 232 million to 286 million yuan, with a year-on-year increase of 3.77% to 27.93% [1] - The growth in Jianda Zhixin's 2025 performance is attributed to two main factors: the rapid development of its core business in centralized operation of medical consumables (SPD), which has a high gross profit margin, enhancing overall profitability [1] - The company has optimized its financial structure, resulting in a year-on-year decrease in interest-bearing liabilities and reduced financing costs through negotiations with financial institutions, positively impacting net profit [1] Group 2 - Jianda Zhixin primarily engages in the direct sales and distribution of medical devices, providing centralized operation services for medical consumables (SPD) to end hospitals [1] - The company's direct sales and distribution products mainly include vascular interventional devices, surgical instruments, IVD (in vitro diagnostic) products, and medical equipment [1]
SPD业务与降本增效双轮驱动 建发致新2025年业绩预增